KLK2 and congenital rubella syndrome: High rates of CRS have been observed with T cell engagers targeting PSMA and STEAP1, in contrast to very low CRS rates reported for pasritamig, a T cell engager targeting KLK2, which may support a relationship with limited normal tissue expression and CRS [14, 15].